Cassava Sciences said that its drug did not significantly reduce cognitive decline in 1,900 people with mild to moderate Alzheimer’s disease. Post navigation Trump Threatens 25% Tariff on Canada and Mexico, Potentially Crippling TradeEV Projects to Get $13 Billion in Federal Loans
